Pharmaceutical - Mergers & Acquisitions, AstraZeneca

Filter

Popular Filters

1 to 25 of 37 results

AstraZeneca to acquire Almirall’s respiratory franchise, for up to $2.1 billion

AstraZeneca to acquire Almirall’s respiratory franchise, for up to $2.1 billion

30-07-2014

Anglo-Swedish pharma major AstraZeneca has entered an agreement to gain rights to the respiratory franchise…

AlmirallAstraZenecaEkliraMergers & AcquisitionsPharmaceuticalRespiratory and Pulmonary

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca board rejects Pfizer’s increased offer

AstraZeneca board rejects Pfizer’s increased offer

02-05-2014

Within just a few hours of US pharma giant Pfizer announcing an increased offer price for Anglo-Swedish…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

02-05-2014

After much speculation and a lightning visit by Pfizer’s chief executive Ian Read to the UK to woo…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca says Pfizer offer “very significantly” undervalues the firm

28-04-2014

Confirming a takeover approach from the US drugs giant, Anglo-Swedish pharma major AstraZeneca issued…

AstraZenecaMergers & AcquisitionsOncologyPfizerPharmaceutical

Pfizer goes public, confirming pursuit of AstraZeneca

Pfizer goes public, confirming pursuit of AstraZeneca

28-04-2014

US pharma giant Pfizer this morning confirmed that it previously submitted a preliminary, non-binding…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer said to be eyeing a $100 billion bid for AstraZeneca

20-04-2014

USA-based Pfizer, the world’s largest pharma company by sales, looks to be on the acquisition trail,…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca acquires full control of Japanese subsidiary

AstraZeneca acquires full control of Japanese subsidiary

26-03-2014

Anglo-Swedish drug major AstraZeneca today announced the completion of the purchase of Sumitomo Chemical’s…

Asia-PacificAstraZenecaJapanMergers & AcquisitionsPharmaceutical

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

Probiodrug sells its CDK9 inhibitor program to AstraZeneca

06-01-2014

Privately-held German company Probiodrug says it has transferred its experimental cyclin-dependent kinase…

AstraZenecaInflammatory diseasesMergers & AcquisitionsOncologyPharmaceuticalProbiodrug

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

Bristol-Myers sells diabetes alliance assets to AstraZeneca for $4.1 billion

19-12-2013

Confirming recent runors, Anglo-Swedish drug major AstraZeneca revealed this morning that it will acquire…

AstraZenecaBristol-Myers SquibbDiabetesExenatide InjectionMergers & AcquisitionsOnglyzaPharmaceutical

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

AstraZeneca boosts oncology portfolio with up to $440 million acquisition

15-10-2013

AstraZeneca revealed this morning that its biologics subsidiary MedImmune has acquired Spirogen, a privately-held…

ADC TherapeuticsAstraZenecaMedImmuneMergers & AcquisitionsOncologyPharmaceuticalSpirogen

AstraZeneca nabs Amplimmune for $500 million

27-08-2013

In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

AstraZeneca to pay up to $1.15 billion to acquire Pearl Therapeutics

10-06-2013

In a further "strategic" bolt-on acquisition for Anglo-Swedish drug major AstraZeneca (LSE: AZN) in less…

AstraZenecaMergers & AcquisitionsPearl TherapeuticsPharmaceuticalPT003Respiratory and Pulmonary

AstraZeneca to buy Omthera in up to $443 million deal

28-05-2013

Anglo-Swedish drug major AstraZeneca's (LSE: AZN) new chief executive Pascal Soriot is making another…

AstraZenecaCardio-vascularEpanovaMergers & AcquisitionsOmthera PharmaceuticalsPharmaceutical

Briefs: Royalty sweetens offer for Elan; AstraZeneca biomarker deal

16-04-2013

US private equity company Royalty Pharma today (April 15) issued a firm improved takeover offer for Ireland-based…

AstraZenecaElanLicensingMergers & AcquisitionsOncologyOxford Cancer BiomarkersPharmaceuticalResearchRoyalty Pharma

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

1 to 25 of 37 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top